All In Biotech

Drug Trial Radar · NCT06663436

A Study on the Immune Response and Safety of a Multicomponent Shigella Vaccine in Preventing Shigellosis in Infants

A Phase 2 Single-Blind, Randomized, Controlled, Single Center Study to Assess the Immunogenicity and Safety of a 2-Dose Schedule With GVGH altsonflex1-2-3 Vaccine in African Infants (H06_02TP)

Last checked: Nov 19, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 200 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

200

Actual

Start

Nov 13, 2024

Primary completion

Oct 21, 2025

Study completion Oct 21, 2025

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Oct 29, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 39 weeks, up to 43 weeks
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study evaluates the immune response and safety of a multicomponent, 2-dose Shigella vaccine in preventing shigellosis in African infants. The candidate vaccine, altSonflex1-2-3, is currently being evaluated in a Phase 2 age de-escalation (from least vulnerable adult population to most vulnerable paediatric population) clinical study in Kenya, with the aim of identifying a preferred dose, using a 3-dose vaccination schedule in infants from 9 months of age (NCT05073003). This Phase 2 clinical study will evaluate the safety and immunogenicity of an alternative 2-dose vaccination schedule.

Conditions

  • Diarrhoea

Interventions

  • altSonflex1-2-3 Dose ABiological

    altSonflex1-2-3 Dose A administered intramuscularly on Day 1 and Day 169

  • altSonflex1-2-3 Dose BBiological

    altSonflex1-2-3 Dose B administered intramuscularly on Day 1 and Day 169

  • altSonflex1-2-3 Dose CBiological

    altSonflex1-2-3 Dose C administered intramuscularly on Day 1 and Day 169

  • TYPHIBEVBiological

    TYPHIBEV administered intramuscularly on Day 1

  • Infanrix hexaCombination product

    Infanrix hexa administered intramuscularly on Day 169

  • MR-VACBiological

    MR-VAC co-administered subcutaneously on Day 1 and Day 169

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Geometric Mean Concentrations (GMCs) of Anti-serotype Specific Shigella Lipopolysaccharide (LPS)/O-Antigen (OAg) Serum Immunoglobulin G (IgG)Time frame: At Day 1 (before administration of Dose 1)
  2. GMCs of Anti-serotype Specific Shigella LPS/OAg Serum IgGTime frame: At Day 29 (28 days after administration of Dose 1)
  3. GMCs of Anti-serotype Specific Shigella LPS/OAg Serum IgGTime frame: At Day 169 (before administration of Dose 2)
  4. GMCs of Anti-serotype Specific Shigella LPS/OAg Serum IgGTime frame: At Day 197 (28 days after administration of Dose 2)
  5. Number of Participants With at Least a 4-fold Increase in Anti-serotype Specific Shigella LPS/OAg Serum IgGTime frame: At Day 29 compared to baseline (before administration of Dose 1 on Day 1)
  6. Number of Participants With at Least a 4-fold Increase in Anti-serotype Specific Shigella LPS/OAg Serum IgGTime frame: At Day 197 compared to baseline (before administration of Dose 1 on Day 1)
  7. Number of Participants With at Least a 4-fold Increase in Anti-serotype Specific Shigella LPS/OAg Serum IgGTime frame: At Day 197 compared to pre-Dose 2 at Day 169

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Kericho, Kenya

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.